Protocols

Heptares bags GPCR tech in $12M G7 buyout; Pfizer reports PhIII success for Herceptin biosim

London-based Heptares has struck a deal to buy Switzerland’s G7 Therapeutics for about $12 million. Heptares was lured to the deal by G7’s expertise in G protein-coupled receptors (GPCRs). G7 isn’t disappearing. It will become the new Zurich-based subsidiary for Heptares, which likes the tech add that expands its work with their STaR platform.

Rack up another Phase III success in the growing biosimilar sector. Pfizer, which is now big into biologic knockoffs, says its copycat of Herceptin came through in a late-stage study. The primary endpoint looked at the objective response rate in a head-to-head comparison on HER2-positive breast cancer, where Herceptin originally made a huge splash in the cancer market. Old drugs like Herceptin, Humira and Avastin have been the target of a long lineup of biosimilar manufacturers, who will soon start carving in to some of the world’s biggest drug franchises.

Early on this year Sanofi stepped up with a deal to partner with Warp Drive Bio on a program to develop aminoglycoside antibiotics to treat drug-resistant Gram-negative infections. And now the two players say that they’ve reached an important milestone in the pact, as the biotech hands over responsibility for the “preclinical and clinical research and development efforts for the novel aminoglycoside antibiotic candidates” uncovered by investigators.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017